

7
IFWPATENT
ATTORNEY DOCKET NO. 10498-00054

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Li-Huei Tsai, Ming-Sum Lee, and
Jonathan Cruz

Serial No.: 10/625,986

Filed: July 24, 2003

Title: COMPOUNDS AND METHODS FOR TREATING
NEURODEGENERATIVE DISORDERS)
)
) Examiner:
)
)
) Art Unit: 1614
)
)
)
)Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

In regard to the above identified application, we are transmitting herewith the attached:

1. Information Disclosure Statement (2 pages),
2. PTO Form-1449 (4 pages),
3. Copies of fifty-five (55) references, and
4. Return postcard.

With respect to additional fees, no fees are due. The Commissioner is nonetheless authorized to charge any additional fees or credit overpayment to Deposit Account No. 19-0733.

Respectfully submitted,

Dated:

October 19, 2004

By

John P. Iwanicki, Reg. No. 34,628
BANNER & WITCOFF, LTD.
28 State Street, 28th Floor
Boston, MA 02109
(617) 720-9600

EV396915045US



PATENT
ATTORNEY DOCKET NO. 10498-00054

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Li-Huei Tsai, Ming-Sum Lee, and) Examiner:
Jonathan Cruz)
)
Serial No.: 10/625,986) Art Unit: 1614
)
Filed: July 24, 2003)
)
Title: COMPOUNDS AND METHODS FOR TREATING)
NEURODEGENERATIVE DISORDERS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.97-1.99, Applicants hereby submit the enclosed PTO Form 1449. Copies of the United States patents cited herein are not being submitted according to the August 5, 2003, U.S. Patent and Trademark Office Official Gazette Notice regarding Information Disclosure Statement filings. Copies of the remaining references are enclosed. Submitted herewith is an English abstract of International Application No. WO 93/01288.

This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. § 1.56 and is being submitted before the mailing date of a first Office Action on the merits.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no

representation is intended as to the relative importance of any portion of the references. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. § 102 or § 103.

Please apply any charges or credits to Deposit Account No. 19-0733.

Respectfully submitted,


Dated: _____

October 19, 2004

By _____



John P. Iwanicki, Reg. No. 34,628
BANNER & WITCOFF, LTD.
28 State Street, 28th Floor
Boston, MA 02109
(617) 720-9600

USPTO Form 1449 		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 10498-00054		Serial No. 10/625,986	
INFORMATION DISCLOSURE CITATION Sheet 1 of 4				Applicants: Li-Huei Tsai et al.			
				Filing Date: July 24, 2003		Group: 1614	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	AA	4,736,866	04/12/98	Leder et al.	800	1	06/22/84
	AB	4,816,567	09/26/89	Cabilly et al.	530	387	04/08/83
	AC	4,870,009	09/26/89	Evans et al.	435	70	12/15/83
	AD	4,873,191	10/10/89	Wagner et al.	435	172.3	08/18/86
	AE	4,873,316	10/10/89	Meade et al.	530	412	01/23/87
	AF	5,223,409	06/29/93	Ladner et al.	435	69.7	03/01/91
	AG	5,225,539	07/06/93	Winter	530	387.3	10/25/91
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation
							YES NO
	AH	EP 0 125 023	11/14/84	Europe			
	AI	EP 0 171 496	02/19/86	Europe			
	AJ	EP 0 173 494	03/05/86	Europe			
	AK	EP 0 184 187	06/11/86	Europe			
	AL	EP 0 264 166	04/20/88	Europe			
	AM	WO 86/01533	05/07/87	PCT			
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	AN	Ahljianian et al., "Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5," <i>Proc. Natl. Acad. Sci.</i> , 97:2910-2915 (2000)					
	AO	Bibb et al., "Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signaling in neurons," <i>Nature</i> , 402:669-671 (1999)					
	AP	Bibb et al., "Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5," <i>Nature</i> , 10:376-380 (2001)					
	AQ	Delalle et al., "Temporal and spatial patterns of expression of p35, a regulatory subunit of cyclin-dependent kinase 5, in the nervous system of the mouse," <i>J. Neurocytol.</i> , 26:283-296 (1997)					
	AR	De Strooper and Annaert, "Proteolytic processing and cell biological functions of the amyloid precursor protein," <i>J. Cell Sci.</i> , 113:1857-1870 (2000)					
EXAMINER					DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.							

USPTO Form 144 9		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 10498-00054		Serial No. 10/625,986		
INFORMATION DISCLOSURE CITATION Sheet 2 of 4				Applicants: Li-Huei Tsai et al.				
				Filing Date: July 24, 2003			Group: 1614	
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
	BA							
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
	BB	WO 87/02671	03/13/86	PCT				
	BC	WO 90/02809	03/22/90	PCT				
	BD	WO 91/17271	11/14/91	PCT				
	BE	WO 92/01047	01/23/92	PCT				
	BF	WO 92/09690	06/11/92	PCT				
	BG	WO 92/15679	09/17/92	PCT				
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	BH	Dhavan and Tsai, "A Decade of Cdk5," <i>Nat. Rev. Mol. Cell Biol.</i> , 2:749-759 (2001)						
	BI	Fischer et al., "Cyclin Dependent Kinase 5 Is Required for Associative Learning," <i>J. Neurosci.</i> , 22(9):3700-3707 (2002)						
	BJ	Grynspan et al., "Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease," <i>Brain Res.</i> , 763:145-158 (1997)						
	BK	Gupta et al., "Life Is a Journey: . . .," <i>Nat. Rev. Genet.</i> , 3:342-357 (2002)						
	BL	Hsiao et al., "Correlative Memory Devicits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <i>Science</i> , 274:99-102 (1996)						
	BM	Keshvara et al., "Cyclin-Dependent Kinase 5 Phosphorylates Disabled 1 Independently of Reelin Signaling," <i>J. Neurosci.</i> , 22:4869-4877 (2002)						
	BN	Khachaturian, "Diagnosis of Alzheimer's Disease," <i>Arch. Neuro.</i> , 42:1097-1105 (1985)						
	BO	Kusakawa et al., "Calpain-dependent Proteolytic Cleavage of the p35 Cyclin-dependent Kinase 5 Activator to p25," <i>J. Biol. Chem.</i> 275:17166 (1999)						
	BP	Ledda et al., "Target-Derived GFR α 1 as an Attractive Guidance Signal for Developing Sensory and Sympathetic Axons via Activation of Cdk5," <i>Neuron.</i> , 36:387-401 (2002)						
	BQ	Lewis et al., "Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein," <i>Nat. Genet.</i> , 25:402-405 (2000)						
EXAMINER					DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.								

USPTO Form 1449		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 10498-00054		Serial No. 10/625,986	
INFORMATION DISCLOSURE CITATION Sheet 3 of 4				Applicants: Li-Huei Tsai et al.			
				Filing Date: July 24, 2003			Group: 1614
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	CA						
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation
							YES NO
	CB	WO 92/18619	10/29/92	PCT			
	CC	WO 92/20791	11/26/92	PCT			
	CD	WO 93/01288	01/21/93	PCT			X
	CE	WO 00/36093	06/22/00	PCT			
	CF	WO 01/57183	08/09/01	PCT			
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	CG	Lewis et al., "Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP," <i>Science</i> , 293:1487-1491 (2001)					
	CH	Li et al., "Regulation of NMDA receptors by cyclin-dependent kinase-5," <i>Proc. Natl. Acad. Sci. USA</i> , 98(22):12742-12747 (2001)					
	CI	Mattson, "Cellular Actions of β -Amyloid Precursor Protein and its Soluble and Fibrillogenic Derivatives," <i>Physiol. Rev.</i> , 77:1081-1132 (1997)					
	CJ	Mayford et al., "Control of Memory Formation through Regulated Expression of a CaMKII Transgene," <i>Science</i> , 274:1678-1683 (1996)					
	CK	Niethammer et al., "NUDEL Is a Novel Cdk5 Substrate that Associates with LIS1 and Cytoplasmic Dynein," <i>Neuron</i> , 28:697-711 (2000)					
	CL	Nikoloic et al., "The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation," <i>Genes Dev.</i> , 10:816-825 (1996)					
	CM	Patrick et al., "Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration," <i>Nature</i> , 402:615-622 (1999)					
	CN	Price et al., "Amyloid beta amyloidosis in Alzheimer's disease," <i>Curr. Op. Neurol.</i> , 8:268-274 (1995)					
	CO	Ramelot et al., "Phosphorylation-induced Structural Changes in the Amyloid Precursor Protein Cytoplasmic Tail Detected by NMR," <i>J. Mol. Biol.</i> , 307:871-884 (2001)					
	CL	Sasaki et al., "A LIS1/NUDEL/Cytoplasmic Dynein Heavy Chain Complex in the Developing and Adult Nervous System," <i>Neuron</i> , 28:681-696 (2000)					
	CQ	Sasaki et al., "Fyn and Cdk5 Mediate Semaphorin-3A Signaling, which Is Involved in REgulation of Dendrite Orientation in Cerebral Cortex," <i>Neuron</i> , 35:907-920 (2002)					
EXAMINER					DATE CONSIDERED		
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.</small>							

USPTO Form 1449		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 10498-00054		Serial No. 10/625,986		
INFORMATION DISCLOSURE CITATION Sheet 4 of 4				Applicants: Li-Huei Tsai et al.				
				Filing Date: July 24, 2003			Group: 1614	
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
	DA							
	DB							
	DC							
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
	DD							
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	DE	Selkoe, "Transplanting cell biology into therapeutic advances in Alzheimer's disease," <i>Nature</i> , 399[Supp]:A23-A31 (1999)						
	DE	Suri et al., "Catecholeminergic Cell Lines from the Brain and Adrenal Glands of Tyrosine Hydroxylase-SV40 T Antigen Transgenic Mice," <i>J. Neurosci.</i> , 13(3):1280-1291 (1993)						
	DG	Tang et al., "An Isoform of the Neuronal Cyclin-dependent Kinase 5 (Cdk5) Activator," <i>J. Biol. Chem.</i> 270(45):26897-26903 (1995)						
	DH	Taniguchi et al., "Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains," <i>FEBS Lett.</i> 489:46-50 (2001)						
	DI	Tomizawa et al., "Localization and Developmental Changes in the Neuron-Specific Cyclin-Dependent Kinase 5 Activator (p35 ^{nck5a}) in the Rat Brain," <i>Neurosci.</i> , 74(2):519-529 (1996)						
	DI	Tsai et al., "p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5," <i>Nature</i> 371:419-423 (1994)						
	DK	Tseng et al., "A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains," <i>FEBS Lett.</i> 523:58-62 (2002)						
	DL	Yang and Hinds, "Increased Ezrin Expression and Activation by CDK5 Coincident with Acquisition of the Senescent Phenotype," <i>Mol. Cell</i> , 11:1163-1176 (2003)						
	DM	Yankner, "Mechanisms of Neuronal Degeneration in Alzheimer's Disease," <i>Neuron</i> , 16:921-932 (1996)						
	DN	Yoo and Lubec, "p25 protein in neurodegeneration," <i>Nature</i> , 411:763-764 (2001)						
	DO	Younkin, "Evidence that Aβ42 Is the Real Culprit in Alzheimer's Disease," <i>Ann. Neurol.</i> 37:287-288 (1995)						
	DP	English abstract of WO 93/01288						
EXAMINER						DQ		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.								